Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1968 2
1970 1
1971 1
1972 1
1973 1
1974 2
1975 2
1976 3
1977 5
1978 3
1979 1
1983 2
1984 2
1985 4
1986 4
1987 2
1988 2
1989 1
1993 1
1994 1
1995 1
1996 1
1997 1
2002 3
2003 4
2004 4
2005 5
2006 1
2007 1
2008 3
2009 3
2010 1
2011 1
2012 1
2013 2
2014 1
2020 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab for Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549. N Engl J Med. 2020. PMID: 32101663 Clinical Trial.
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651. N Engl J Med. 2022. PMID: 35139274 Clinical Trial.
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Garnett S, Lindemann JP, Sapunar F, Martin M. Di Leo A, et al. Among authors: lichinitser mr. J Clin Oncol. 2010 Oct 20;28(30):4594-600. doi: 10.1200/JCO.2010.28.8415. Epub 2010 Sep 20. J Clin Oncol. 2010. PMID: 20855825 Clinical Trial.
An attempt to prevent senescence: a mitochondrial approach.
Skulachev VP, Anisimov VN, Antonenko YN, Bakeeva LE, Chernyak BV, Erichev VP, Filenko OF, Kalinina NI, Kapelko VI, Kolosova NG, Kopnin BP, Korshunova GA, Lichinitser MR, Obukhova LA, Pasyukova EG, Pisarenko OI, Roginsky VA, Ruuge EK, Senin II, Severina II, Skulachev MV, Spivak IM, Tashlitsky VN, Tkachuk VA, Vyssokikh MY, Yaguzhinsky LS, Zorov DB. Skulachev VP, et al. Among authors: lichinitser mr. Biochim Biophys Acta. 2009 May;1787(5):437-61. doi: 10.1016/j.bbabio.2008.12.008. Epub 2008 Dec 29. Biochim Biophys Acta. 2009. PMID: 19159610 Free article. Review.
Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.
Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Malorni L, Garnett S, Rukazenkov Y, Martin M. Di Leo A, et al. Among authors: lichinitser mr. J Natl Cancer Inst. 2014 Jan;106(1):djt337. doi: 10.1093/jnci/djt337. Epub 2013 Dec 7. J Natl Cancer Inst. 2014. PMID: 24317176 Free PMC article. Clinical Trial.
Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia.
Ralston SH, Thiébaud D, Herrmann Z, Steinhauer EU, Thürlimann B, Walls J, Lichinitser MR, Rizzoll R, Hagberg H, Huss HJ, Tubiana-Hulin M, Body JJ. Ralston SH, et al. Among authors: lichinitser mr. Br J Cancer. 1997;75(2):295-300. doi: 10.1038/bjc.1997.48. Br J Cancer. 1997. PMID: 9010041 Free PMC article. Clinical Trial.
Antibody response to a non-conserved C-terminal part of human histone deacetylase 3 in colon cancer patients.
Shebzukhov YV, Koroleva EP, Khlgatian SV, Belousov PV, Kuz'mina KE, Radko BV, Longpre F, Lagarkova MA, Kadachigova TS, Gurova OV, Meshcheryakov AA, Lichinitser MR, Knuth A, Jager E, Kuprash DV, Nedospasov SA. Shebzukhov YV, et al. Among authors: lichinitser mr. Int J Cancer. 2005 Dec 10;117(5):800-6. doi: 10.1002/ijc.21240. Int J Cancer. 2005. PMID: 15981215 Free article.
75 results